- Home
- ALXO vs INO Comparison
ALXO vs INO Comparison
Compare ALXO & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- INO
- Stock Information
- Founded
- ALXO 2015
- INO 1979
- Country
- ALXO United States
- INO United States
- Employees
- ALXO N/A
- INO N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- INO Medical/Dental Instruments
- Sector
- ALXO Health Care
- INO Health Care
- Exchange
- ALXO Nasdaq
- INO Nasdaq
- Market Cap
- ALXO 76.5M
- INO 75.4M
- IPO Year
- ALXO 2020
- INO 1998
- Fundamental
- Price
- ALXO $1.74
- INO $2.08
- Analyst Decision
- ALXO Buy
- INO Buy
- Analyst Count
- ALXO 6
- INO 6
- Target Price
- ALXO $11.00
- INO $17.00
- AVG Volume (30 Days)
- ALXO 1.1M
- INO 1.2M
- Earning Date
- ALXO 03-06-2025
- INO 03-05-2025
- Dividend Yield
- ALXO N/A
- INO N/A
- EPS Growth
- ALXO N/A
- INO N/A
- EPS
- ALXO N/A
- INO N/A
- Revenue
- ALXO N/A
- INO $203,413.00
- Revenue This Year
- ALXO N/A
- INO N/A
- Revenue Next Year
- ALXO N/A
- INO $2,290.97
- P/E Ratio
- ALXO N/A
- INO N/A
- Revenue Growth
- ALXO N/A
- INO N/A
- 52 Week Low
- ALXO $1.19
- INO $1.74
- 52 Week High
- ALXO $17.83
- INO $14.75
- Technical
- Relative Strength Index (RSI)
- ALXO 53.13
- INO 39.63
- Support Level
- ALXO $1.56
- INO $1.83
- Resistance Level
- ALXO $1.94
- INO $2.39
- Average True Range (ATR)
- ALXO 0.16
- INO 0.17
- MACD
- ALXO -0.01
- INO 0.11
- Stochastic Oscillator
- ALXO 50.00
- INO 51.56
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.